PFE
Pfizer Inc. (PFE)
$53.361.16%▲
Key Stats
$52.91
Day's Range
$53.4509
$37.65
52-Week Range
$60.75
| Returns | |
| 1 month return | 2.24% |
| 3 month return | 6.38% |
| 1 year return | 29.88% |
| 5 year return | 56.11% |
Company Information
“Pfizer Inc., founded in 1849 by Charles Pfizer and Charles F. Erhart, is an American Biotechnology and Pharmaceutical giant. It is currently headquartered in New York City, United States with worldwide operations and distributions. To ensure that the medicinal and vaccine requirements of every patient and individual are met, Pfizer has been adopting a rigorous and scientific approach towards its supply chain. They now have a network of 58 manufacturing sites around the world under Pfizer Global Supply (PGS).
To further expand its operations in the research and pharmaceutical sphere, it entered various merger and acquisitions deals with other players including Wyeth, Pharmacia, Warner-Lambert, Innopharma, etc. Its primary focus areas include internal medicine, rare diseases, vaccines, inflammation, immunology, oncology, and anti-infectives. They have major R&D platforms in the fields of gene therapy, precision medicine, biosimilars, medicinal sciences, and maternal immunizations.
Pfizer Is traded under the ticker symbol of PFE. The financials of Pfizer are as follows: While Pfizer clocked a revenue of $41.908 billion for 2020, its net income amounted to $6985 million for the same period. Pfizer has made significant contributions in the fight against Covid-19 and has been successful in the early development of the Pfizer-BioNTech Vocid-19 vaccine. In 2020, Pfizer achieved the Top Employer Certification for the 5th year in the UK. Going by the revenue, Pfizer is the 4th largest pharmaceutical company globally and the 3rd largest in terms of market capitalization. It is currently traded in NYSE and other indices, including S&P 100, S&P 500, and Russell 1000 Index.
Currently Pfizer Inc. has a market cap of $289.75 Billion. It has a P.E ratio of 12.1. The shares of Pfizer Inc. are trading at $52.75.
” .
| Organization | Pfizer Inc. |
| Employees | 78500 |
| CEO | Albert Bourla |
| Industry | Health Technology |
Analyst Recommendation
based on 30 analysts ratings
Buy
53%
Buy
46%
Hold
0%
Sell
Based on 30 Wall street analysts offering stock ratings for Pfizer Inc.(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 15.28%Current
$52.75
Target
$60.81
Recommendation Trend
Based on 30 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 16 | 16 | 13 |
| Hold | 14 | 13 | 15 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | HOLD |
Company Financials
Highlights
| Market Capitalization | 280.9B |
| Book Value | 13.74 |
| Dividend Share | 1.56 |
| Dividend Yield | 1.56 |
| Earnings Share | 3.85 |
| PE Ratio | 12.9061 |
| PEG Ratio | 1.17 |
| Wall Street Target Price | 60.29 |
Valuation
| Trailing PE | 12.91 |
| Forward PE | 6.96 |
| Price/Sales (ttm) | 3.46 |
| Price/Book (mrq) | 3.52 |
| Enterprise Value | 277.8B |
| Enterprise Value/Revenue | 3.42 |
| Enterprise Value/Ebitda | 9.02 |
Technicals
| Beta | 0.72 |
| 50 Day MA | 50.67 |
| 200 Day MA | 49.17 |
Sustainability
| Rating Date | 2019-01-01 |
| Total Esg | 33.15 |
| Total Esg Percentile | 60.0 |
| Environment Score | 7.0 |
| Environment Score Percentile | 6.0 |
| Social Score | 18.47 |
| Social Score Percentile | 6.0 |
| Governance Score | 13.68 |
| GovernanceScorePercentile | 6.0 |
| Controversy Level | 3.0 |
Institutional Holdings
Vanguard Group Inc
8.54%
BlackRock Inc
7.31%
State Street Corporation
5.11%
Capital World Investors
3.92%
Wellington Management Company LLP
3.86%
Geode Capital Management, LLC
1.87%
Discover more
Pfizer Inc. (PFE) Earnings for Q4 (2021): Key Highlights
Revenue
The revenue reported by Pfizer for the December quarter was at $23.8 billion, slightly below the Street estimate of $24.12 billion. The overall sales increased by 105% from the year-ago period. Higher sales were driven by the sales of Pfizer and German partner BioNTech’s BNTX COVID-19 vaccine, Comirnaty. International revenue increased to $16.2 billion, a rise of 181%. US revenue rose 32% to $7.68.
Other updates
Adjusted selling, informational and administrative (SI&A) expenses rose 10% (operationally) in the December quarter to $3.94 billion. Adjusted R&D expenses rose 14% to $3.5 billion due to costs related to the development of COVID-19 treatment programs and other pipeline medicines.
Update on Paxlovid
In the last week of December 2021, the FDA granted Emergency Use Authorization (EUA) to Paxlovid, for the treatment of mild-to-moderate COVID-19 in patients at increased risk of hospitalizations or death. Paxlovid contributed $76 million to US sales in the fourth quarter of 2021.
2022 Outlook
The company expects revenue to be between $98 billion and $102 billion. The revenue guidance is below analysts' expectations of $108.6 billion. The revenue guidance includes approximately $32.0 billion in sales from Comirnaty and $22 billion from Paxlovid. Adjusted EPS are expected to be in a range of $6.35 to $6.55. R&D expenses are expected to be between $10.5 and 11.5 billion.
Target price
The 20 analysts offering 12-month price forecasts for Pfizer Inc have a median target of $58.75, with a high estimate of $76 and a low estimate of $49.